TAYSHA GENE THERAPIES INC. - COMMON STOCK

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 16:30:45 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

22 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 08:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 08:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12

05 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

26 Jun 2024 09:14:46 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

25 Jun 2024 18:34:46 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

18 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

12 Jun 2024 07:00:43 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

14 May 2024 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

07 May 2024 16:05:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 16:05:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

02 May 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 08:00:00 By Nasdaq GlobeNewswire